Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.65
Bid: 0.60
Ask: 0.70
Change: -0.10 (-13.33%)
Spread: 0.10 (16.667%)
Open: 0.75
High: 0.75
Low: 0.65
Prev. Close: 0.75
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re Investment

4 Apr 2016 08:57

RNS Number : 0259U
Onzima Ventures PLC
04 April 2016
 

Onzima Ventures PLC

("Onzima" or the "Company")

Investee company N4 Pharma announces messenger RNA vaccine program

Onzima is pleased to announce that N4 Pharma Limited ("N4 Pharma") its 49%-owned investee company, has extended its relationship with the University of Queensland ("Uniquest") to include the exclusive global rights to commercialise their nano particle vaccine delivery system for messenger RNA (mRNA) particles. This adds to the rights it already has for plasmid DNA and certain subunit vaccines.

Under this agreement N4 Pharma will undertake further research and experimentation with Uniquest to develop a strong in-vitro data package demonstrating the ability of these vectors to achieve high protective loading of pDNA and mRNA and demonstrate their strong transfection capability.

N4 Pharma CEO Nigel Theobald commented:

"mRNA is an exciting area of therapeutic treatment in oncology and early encouraging results with our plasmid DNA research show strong pDNA loading onto the silica vesicle and excellent transfection being achieved.

Over the next few months we will continue to undertake experiments to demonstrate the capability of our vectors for both pDNA and mRNA, publishing the data when we can with a view to looking to engage with potential partners in the second half of 2016 to either work with their own particles or potentially acquire the rights to particles ourselves which we can then seek to take forward using these vectors.

The recent investment by Onzima Ventures has allowed us to develop our intellectual property portfolio and create two extremely strong drug delivery/reformulation platforms, one for small molecules and another for vaccines and oncology treatments. Our aim now is to develop strong commercial propositions using our IP and seek partnerships and funds to take forward specific projects."

For further information please contact:

Onzima Ventures PLC Tel: +44 (0) 1622 717700

Gavin Burnell, Luke Cairns

 

Nominated Adviser

Cairn Financial Advisers LLP Tel: +44 (0) 20 7148 7900

Sandy Jamieson, Liam Murray

 

Broker

Peterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 0930

Guy Miller, Lucy Williams

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXLLESLKEEF
Date   Source Headline
20th Apr 201612:12 pmRNSHolding(s) in Company
20th Apr 20167:00 amRNSFiling of Patents by 49% - owned N4 Pharma
11th Apr 201610:03 amRNSSale of Investment
4th Apr 20168:57 amRNSUpdate re Investment
22nd Mar 20164:14 pmRNSInvestment
18th Mar 20161:55 pmRNSHolding(s) in Company
14th Mar 20169:44 amRNSInvestment
11th Mar 201612:49 pmRNSUpdate re Investment
10th Mar 20163:11 pmRNSInvestment
4th Mar 20161:05 pmRNSFurther information re N4 investment and update
1st Mar 201610:00 amRNSInvestment
8th Jan 201611:18 amRNSDisposal
8th Jan 201610:04 amRNSHolding(s) in Company
11th Dec 20153:34 pmRNSHolding(s) in Company
7th Dec 201511:07 amRNSInvestment
3rd Nov 20154:53 pmRNSDirector's Details - Update
15th Oct 20155:16 pmRNSChange of Name
14th Oct 20153:43 pmRNSResult of EGM
25th Sep 20157:00 amRNSNotice of EGM
23rd Sep 20155:11 pmRNSHalf Yearly Report
27th May 20157:00 amRNSNotice of AGM
12th May 20152:13 pmRNSFinal Results
2nd Dec 20143:14 pmRNSDirectorate Change
29th Sep 20149:37 amRNSHalf Yearly Report
22nd Sep 20143:00 pmRNSChange of Adviser
25th Jun 20143:23 pmRNSResult of AGM
28th May 20147:00 amRNSAvailability of Accounts and Notice of AGM
23rd May 20147:00 amRNSFinal Results
10th Sep 201312:07 pmRNSMexico Exhibition
2nd Sep 20137:00 amRNSSouth African Power Purchase Agreement
2nd Sep 20137:00 amRNSHalf Yearly Report
25th Jul 20137:00 amRNSOrder from the Kingdom of Saudi Arabia
1st Jul 20134:35 pmRNSResult of AGM
6th Jun 20137:00 amRNSNotice of AGM
12th Feb 20137:00 amRNSTrading Statement
16th Oct 20127:00 amRNSNew Solar Installation
12th Sep 20127:00 amRNSInterim Results
7th Sep 20127:00 amRNSChange of Nominated Adviser and Broker
27th Jun 20129:36 amRNSResult of AGM
29th May 20122:34 pmRNSNotice of AGM
8th May 20127:00 amRNSFinal Results
31st Jan 20127:00 amRNSTrading Update
17th Aug 20117:00 amRNSHalf Yearly Report
7th Jul 20117:00 amRNSResult of AGM, board change and change of name
30th Jun 20117:00 amRNSTotal Voting Rights
14th Jun 20117:00 amRNSIssue of Equity
9th Jun 20117:00 amRNSApproved installer status
2nd Jun 20117:00 amRNSNotice of AGM/proposed change of name
23rd May 20117:00 amRNSFinal Results
5th Apr 20117:00 amRNSNew Order for Green Technology Products Division

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.